Table 2.
Clinical and Demographic Characteristics of the HPFS Prostatectomy Cohort (N = 572), 1986 to 2000*
| Characteristic | No. | % |
|---|---|---|
| Total, N | 572 | |
| Age at diagnosis, years | ||
| Median | 66.3 | |
| Range | 47.0-79.8 | |
| Race | ||
| White | 519 | 95.6 |
| African American | 9 | 1.7 |
| Asian | 9 | 1.7 |
| Other | 6 | 1.1 |
| Pathologic tumor stage | ||
| T2 | 398 | 70.2 |
| T3a† | 98 | 17.3 |
| T3b‡ | 41 | 7.2 |
| T4/N1 | 30 | 5.3 |
| Gleason grade | ||
| 2-5 | 27 | 4.7 |
| 6 | 128 | 22.4 |
| 7 | 333 | 58.2 |
| 3 + 4 | 199 | 34.7 |
| 4 + 3 | 134 | 23.5 |
| 8-10 | 84 | 14.7 |
| Year of diagnosis | ||
| 1986-1989, pre-PSA era | 42 | 7.3 |
| 1990-1993, peri-PSA era | 174 | 30.4 |
| 1994-2000, PSA era | 356 | 62.2 |
| PSA at diagnosis, ng/mL | ||
| Median | 7.0 | |
| Range | 0.4-77 | |
| Follow-up time, years | ||
| Median | 9.9 | |
| Range | 0.8-19.9 | |
| Body mass index | ||
| Median | 25.1 | |
| Range | 17.8-38.3 | |
Abbreviations: HPFS, Health Professionals Follow-Up Study; PSA, prostate-specific antigen.
*
Numbers do not add up to 572 if data are missing.
†
T3a indicates penetration through capsule wall.
‡
T3b indicates involvement of the seminal vesicles.